Published in Cancer Treat Rev on October 01, 2011
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93
A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening. Exp Biol Med (Maywood) (2014) 0.89
Effect of type of TAG fatty acids on lutein and zeaxanthin bioavailability. Br J Nutr (2012) 0.79
Prognostic significance of liver parameters at 1-year follow-up in children and adults undergoing myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant (2015) 0.75
Usefulness of ascitic fluid lactoferrin levels in patients with liver cirrhosis. BMC Gastroenterol (2016) 0.75
Biomarkers and non-invasive tests for gastrointestinal mucositis. Support Care Cancer (2017) 0.75
Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer (2005) 1.01
Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther (2007) 0.96
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab (2009) 0.93
Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs (2008) 0.93
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93
Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys (2005) 0.92
Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol (2012) 0.91
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol (2009) 0.91
Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) (2007) 0.89
Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) (2010) 0.85
Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother Pharmacol (2009) 0.85
Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy (2007) 0.85
Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma. J Gastrointest Surg (2015) 0.84
Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Curr Opin Support Palliat Care (2013) 0.84
Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther (2007) 0.80
Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs (2008) 0.80
Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Support Care Cancer (2014) 0.79
Technological advances in mucositis research: new insights and new issues. Cancer Treat Rev (2008) 0.78
New pharmacotherapy options for chemotherapy-induced alimentary mucositis. Expert Opin Biol Ther (2014) 0.77
Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy (2011) 0.77
Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test. J Support Oncol (2013) 0.76
Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. Int J Exp Pathol (2011) 0.76
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Support Palliat Care (2016) 0.76
TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity? Int J Cancer (2014) 0.76
Editorial Comment: Does gut-derived inflammation enhance pain signaling following chemotherapy in a Toll-like receptor 4-dependent manner? Curr Opin Support Palliat Care (2015) 0.75